RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, not showing statistically significant differences in outcomes. Improved results were seen with the combination of emtricitabine/tenofovir disoproxil + rosuvastatin + colchicine. NCT04359095
Gaitán-Duarte et al., 7/10/2021, Randomized Controlled Trial, Colombia, South America, preprint, 17 authors, this trial uses multiple treatments in the treatment arm (combined with rosuvastatin) - results of individual treatments may vary.
risk of death, 19.0% lower, RR 0.81, p = 0.43, treatment 22 of 153 (14.4%), control 28 of 161 (17.4%), adjusted per study, 28 days.
risk of mechanical ventilation, 15.0% lower, RR 0.85, p = 0.15, treatment 27 of 136 (19.9%), control 27 of 140 (19.3%), adjusted per study.
risk of ICU admission, 1.0% lower, RR 0.99, p = 0.97, treatment 19 of 113 (16.8%), control 18 of 114 (15.8%), adjusted per study.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.